http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03016313-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4884983cf128a793a8b27a24f50e093b
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
filingDate 2002-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb46b7ba905483a8c55458c19ac46c56
publicationDate 2003-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-03016313-A1
titleOfInvention New compounds for treating impotence
abstract The invention relates to new compounds of formula (I) which are selective inhibitors of phosphodiesterase, their pharmaceutically receptable salts or their configuration isomers. This invention also provides a method for preparing the compounds of formula (I), and new intermediates which are involved in the routes of synthesizing the compounds of formula (I). The compounds of formula (I) according to the present invention are effective in treating impotence diseases, especially in treating male erectile dysfunction. They also have such characteristics as longer duration of effect and lower toxicity.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1695976-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1695976-A1
priorityDate 2001-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0463756-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9962905-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0107441-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419475145
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8471
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426228520
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7412
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23665647
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398744
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419525298
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419521000
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24638
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16723172
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10439
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457502397
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450645223
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426124650
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6950261
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID67252
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590271
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426177170
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553602
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419531751
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419546621
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11380071
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456405831
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419529444
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24648
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419546206
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID55717
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24386

Total number of triples: 52.